The text starts here.

News Release

FOR IMMEDIATE RELEASE
August 30, 1999

PARIET, A PROTON PUMP INHIBITOR, RECEIVES MARKETING APPROVAL IN THE EU FOR GORD MAINTENANCE THERAPY

Tokyo (August 30, 1999) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that the proton pump inhibitor PARIET (U.S. trade name ACIPHEX) has received agreement for approval from all 15 EU countries for the new indication of maintenance of gastro-oesophageal reflux disease (GORD).


PARIET is classified as a proton pump inhibitor and demonstrates strong proton pump inhibition at the final stage of acid secretion by blocking the function of the enzyme responsible for stomach acid production. PARIET is available in 20 mg or 10 mg enteric-coated tablets prescribed once daily for the maintenance of gastro-oesophageal reflux disease (GORD). PARIET is also approved in all EU countries for the treatment of symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD), active duodenal and active benign gastric ulcers.


PARIET was cleared for marketing in all 15 EU countries through the Mutual Recognition Procedure in September 1998, and Eisai sales began in the United Kingdom in September 1998, and in Germany in December 1998. Eisai Co., Ltd. and Janssen-Cilag currently copromote PARIET in the United Kingdom, Germany, and ACIPHEX the United States. PARIET sales in Japan began in 1997 and in the United States, under the trade name ACIPHEX, in August 1999.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.3 billion in 1998 with greater than 15 percent of sales spent for research and development.


Note: Gastro-oesophageal reflux disease (GORD) results from the flow of stomach contents back into the oesophagus which can cause heartburn, ulceration, inflammation and difficulty in swallowing. Maintenance therapy prevents a recurrence of gastro-oesophageal reflux disease (GORD).


PARIET is a trademark of Eisai Co., Ltd.
ACIPHEX is a trademark of Eisai Co., Ltd.